This article is part of a special supplement published by Nephrology News & Issues in the February 2014 issue entitled, "Iron therapy and a quarter century of ESAs: What have we learned?" The ...

Washington, DC - Intravenous iron sucrose therapy as an adjuvant treatment to erythropoiesis-stimulating agents (ESA) can help effectively battle anemia in peritoneal-dialysis (PD) patients and avoid ...

Vascular Calcification mortality non-dialysis CKD Study shows benefit of initiating epoetin beta therapy at hemoglobin levels not less than 10 g/dL in non-dialysis CKD patients. Earlier treatment of ...

statin-therapy_1115 Using statins for more than 3 months was significantly associated with 85% lower odds of ESA hyporesponsiveness in CKD patients. Statin therapy may curb hyporesponsiveness to ...

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), in end-stage ...

Tucson, AZ - Intravenous iron therapy is superior to oral iron in nondialysis-dependent chronic kidney disease (ND-CKD) accompanied by moderate-anemia and low-iron indices and has the potential to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The use of erythropoietin-stimulating agents for ...

The new KDIGO anaemia guidelines represent a bold, sensible, and patient-centred approach to anaemia management in patients with chronic kidney disease. Recommendations regarding haemoglobin targets, ...

Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS. Bruce Feinberg, DO: Amer, invariably, there are patients who aren’t going ...

In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy. Specific factors may predict better initial response to darbepoetin alfa in patients ...

THOUSAND OAKS, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will review the results from TREAT (the Trial to Reduce Cardiovascular Events with ...